Gubra ApS and Bayer AG collaborate to develop next generation cardiorenal treatments

  • Gubra ApS announced today a new research collaboration and license agreement with Bayer AG for the development of novel peptide therapeutics to treat cardiorenal disease.
  • Cardiorenal disease is an umbrella term for acute and chronic disorders, involving both the heart and the kidney.
  • Gubra to receive an upfront payment and potential future development and commercialization milestones of up to € 216 million.

HØRSHOLM, Denmark I September 20, 2021 I Gubra announced the signing of a research collaboration and license agreement with Bayer AG for the development of novel peptide therapeutics to treat cardiorenal diseases. The collaboration utilizes Gubra’s machine learning-based peptide drug discovery platform (streaMLine) for fast screening and identification of potent therapeutic peptide candidates.

The joint research program between Gubra and Bayer AG aims at further maturing a novel therapeutic peptide for the potential treatment of cardiorenal disease. Cardiorenal disease is an umbrella term for acute and chronic disorders involving both the heart and the kidney. These disorders are associated with a high morbidity and mortality globally and currently available treatments are not optimal for all patients. Consequently, cardiorenal diseases cause a significant burden on health care systems around the world.

The collaboration will combine Gubra’s unique peptide drug discovery capabilities and use of advanced technologies with Bayer AG’s expertise in development of innovative medicines. The extensive experience in both companies with drug profiling in preclinical translational disease models also form an essential part of the collaboration.

“We are very pleased to enter this research collaboration and license agreement with Bayer,” said Henrik Blou, CEO of Gubra. “We have used streaMLine, our proprietary machine learning-based target and peptide drug discovery platform, to conceive this promising program currently undergoing preclinical maturation. We are pleased that the potential of our technology is being recognized by such a qualified partner capable of advancing innovative medicines into the clinic.”

Under the terms of the agreement, Gubra to receive an upfront payment and potential future development and commercialization milestones of up to € 216 million.

Contact
Gubra ApS
Henrik Blou, CEO
Phone: +45 2861 6845
This email address is being protected from spambots. You need JavaScript enabled to view it.

About Gubra
Founded in 2008, Gubra is a privately held biotech company located in Denmark delivering scientific counselling, contract research services, and projects for co-development in four main focus areas: Obesity, diabetes, NASH and diabetic complications. Gubra experts cover a number of preclinical disciplines: in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. Gubra has a hybrid business model with a pipeline of early target and drug discovery programs aimed for partnering while also delivering preclinical services to customers by combining cutting-edge technology with our accumulated experience and proven methodology. Gubra is an abbreviation for GUt and BRAin, the original key focus areas of research and expertise. For more information, please visit our website at www.gubra.dk.

For more information, please visit our website at www.gubra.dk

SOURCE: Gubra

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top